• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    EDP Renewables Starts Construction on 240-Megawatt Texas Solar Park

    9/20/22 10:00:00 AM ET
    $BMY
    $FB
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Internet and Information Services
    Technology
    Get the next $BMY alert in real time by email

    Houston, Texas, Sept. 20, 2022 (GLOBE NEWSWIRE) -- EDP Renewables North America (EDPR NA), a leading renewable energy developer and operator in North America, announces the start of construction on its 240-megawatt (MW) Cattlemen I Solar Park in Milam County, Texas.

    Cattlemen Solar Park, which was developed and constructed and will be operated by EDPR NA, will bring a wealth of economic benefits to Milam County and the greater central Texas region through millions of dollars that will be paid to local landowners, a projected $55 million in taxes that will be paid to support area schools and community services, and millions of dollars that will be spent locally during the project's construction and multi-decade operational life. Cattlemen will also support local jobs – both in the 400 employment opportunities created during construction and the several full-time team members who will be employed to safely run and perform routine maintenance on the park during operations. Once online in 2023, Cattlemen's generation will be equivalent to the consumption of more than 37,000 average Texas homes. Cattlemen will also save more than 304 million gallons of water and avoid more than 271,000 tons of CO2 each year that would be needed by conventional generation sources to produce the same amount of energy capacity as the solar park.

    "Cattlemen is EDP Renewables' first solar park in Texas and will soon be our largest operational solar park in our North American portfolio," Kris Cheney, EDP Renewables North America Executive Vice President – Central and Western Regions and Mexico, Environmental Affairs, and Energy Storage Analytics said. "The Milam County community has been a great partner throughout Cattlemen's development. As we move closer to operation, we look forward to continuing that partnership as a contributing member of the community and expanding upon our relationship with the landowners, local officials, and residents."

    EDP Renewables is a clean energy leader in Texas. The company's North American headquarters is in Houston and it operates six wind energy projects throughout the state, including two phases of the Lone Star Wind Farm, two phases of the Los Mirasoles Wind Farm, the Reloj del Sol Wind Farm, and the Wildcat Creek Wind Farm. The projects' total operating capacity is 1,089 MW, which generate enough electricity to annually power more than 236,000 average homes in Texas. EDPR's Texas presence totals an estimated $1.9 billion in capital investment and more than 550 jobs.

    Cattlemen has two long-term commercial agreements in-place for the project: a 156-MW power purchase agreement (PPA) with Meta (NYSE:FB) and a 60-MW PPA with Bristol Myers Squibb (NYSE:BMY). Cattlemen Solar Park is the second PPA that EDP Renewables and Meta have executed; the companies' first PPA was a 139-MW contract for EDPR NA's 200-MW Headwaters II Wind Farm in Indiana.

    Multimedia resources include:

    • EDPR NA: Fact Sheet
    • Cattlemen Solar Park: Fact Sheet
    • EDPR NA Texas: Fact Sheet
    • Economic benefits of solar: Fact Sheet
    • Solar Power in North America: Video

    ###

    About EDP Renewables North America

    EDP Renewables North America LLC (EDPR NA), its affiliates, and its subsidiaries develop, construct, own, and operate wind farms and solar parks throughout North America. Headquartered in Houston, Texas, with 58 wind farms, nine solar parks, and eight regional offices across North America, EDPR NA has developed more than 8,800 megawatts (MW) and operates more than 8,200 MW of onshore utility-scale renewable energy projects. With more than 950 employees, EDPR NA's highly qualified team has a proven capacity to execute projects across the continent.

    For more information, visit www.edpr.com/north-america.

    About EDP Renewables

    EDPR NA is a wholly owned subsidiary of EDP Renewables (Euronext: EDPR), a global leader in

    the renewable energy sector. EDPR is the fourth largest renewable energy producer worldwide with a presence in 28 markets across Europe, North America, South America and Asia Pacific. Based in Madrid and with main regional offices in Houston, São Paulo and Singapore, EDPR has a robust development portfolio with first-class assets and a market-leading operational capability in renewables. These include wind onshore, utility scale and distributed solar, wind offshore (through its 50/50 JV - OW) and technologies complementary to renewables such as batteries and green hydrogen. EDPR's employee-centered policies resulted in its recognition as a Top Workplace 2022 in the United States, Top Employer 2022 in Europe (Spain, Italy, France, Romania, Portugal and Poland) and Brazil, as well as its inclusion in the Bloomberg Gender-Equality Index.

    EDPR is a division of EDP (Euronext: EDP), a leader in the energy transition with a focus on decarbonization. Besides its strong presence in renewables (with EDPR and hydro operations), EDP has an integrated utility presence in Portugal, Spain and Brazil including electricity networks, client solutions and energy management. EDP – EDPR's main shareholder – has been listed on the Dow Jones Index for 14 consecutive years, recently being named the most sustainable electricity company on the Index.

    Attachments

    • EDP Renewables Logo
    • Cattlemen Solar Park Logo


    Blair Matocha
    EDP Renewables North America
    713-356-2415
    [email protected]
    
    Get the next $BMY alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $BMY
    $FB

    CompanyDatePrice TargetRatingAnalyst
    Bristol-Myers Squibb Company
    $BMY
    4/22/2025$55.00Neutral
    Cantor Fitzgerald
    Bristol-Myers Squibb Company
    $BMY
    4/22/2025Overweight
    Piper Sandler
    Bristol-Myers Squibb Company
    $BMY
    12/16/2024$70.00Hold → Buy
    Jefferies
    Bristol-Myers Squibb Company
    $BMY
    12/10/2024$63.00Neutral
    BofA Securities
    Bristol-Myers Squibb Company
    $BMY
    11/15/2024Peer Perform
    Wolfe Research
    Bristol-Myers Squibb Company
    $BMY
    11/13/2024Neutral → Outperform
    Daiwa Securities
    Bristol-Myers Squibb Company
    $BMY
    11/12/2024$73.00Market Perform → Outperform
    Leerink Partners
    Bristol-Myers Squibb Company
    $BMY
    10/25/2024$75.00 → $55.00Buy → Neutral
    Citigroup
    More analyst ratings

    $BMY
    $FB
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Bristol Myers Squibb Announces Dividend

      Bristol Myers Squibb (NYSE:BMY) today announced that its Board of Directors has declared a quarterly dividend of sixty-two cents ($0.62) per share on the $0.10 par value common stock of the company. The dividend is payable on August 1, 2025, to stockholders of record at the close of business on July 3, 2025. In addition, the Board of Directors has declared a quarterly dividend of fifty cents ($0.50) per share on the company's $2.00 convertible preferred stock, payable on September 2, 2025, to stockholders of record at the close of business on August 5, 2025. About Bristol Myers Squibb: Transforming Patients' Lives Through Science At Bristol Myers Squibb, our mission is to discover, de

      6/17/25 4:16:00 PM ET
      $BMY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Bristol Myers Squibb Presents First Data from the Marginal Zone Lymphoma Cohort of the Transcend FL Trial Demonstrating Deep and Durable Responses with Breyanzi (lisocabtagene maraleucel)

      95.5% of patients with relapsed or refractory marginal zone lymphoma (MZL) treated with lisocabtagene maraleucel (liso-cel) achieved a response, with 62.1% achieving complete response and 88.6% maintaining a response at 24 months New data show liso-cel demonstrated high rates of durable responses and a consistent safety profile in a fifth cancer type, the most of any CD19-directed CAR T cell therapy Additional liso-cel data at ICML 2025 further reinforce BMS' commitment to unlocking the full potential of this therapy for patients Bristol Myers Squibb (NYSE:BMY) today announced the first disclosure of the primary analysis results of the marginal zone lymphoma (MZL) cohort of TRANSCEND

      6/16/25 6:59:00 AM ET
      $BMY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Bristol Myers Squibb Presents Data Across Targeted Protein Degradation Research Including CELMoD™ Agents and BCL6 Ligand-Directed Degrader at EHA 2025

      Innovative Agents Highlight Growth of Targeted Protein Degradation Platform and BMS' Leadership in Innovative Cancer Therapies Bristol Myers Squibb (NYSE:BMY) today announced the presentation of new data from its targeted protein degradation platform during the 2025 European Hematology Association (EHA) Annual Congress being held from June 12-15 in Milan, Italy. Presentations feature updated clinical findings on the company's investigational oral CELMoD™ agents mezigdomide and iberdomide in multiple myeloma, and golcadomide in non-Hodgkin lymphoma, as well as the first results evaluating the company's first-in-class, oral BCL6 ligand-directed degrader (LDD) (BMS-986458) in non-Hodgkin lym

      6/12/25 6:59:00 AM ET
      $BMY
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BMY
    $FB
    SEC Filings

    See more
    • SEC Form 11-K filed by Bristol-Myers Squibb Company

      11-K - BRISTOL MYERS SQUIBB CO (0000014272) (Filer)

      6/6/25 2:25:42 PM ET
      $BMY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 11-K filed by Bristol-Myers Squibb Company

      11-K - BRISTOL MYERS SQUIBB CO (0000014272) (Filer)

      6/6/25 2:24:57 PM ET
      $BMY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 11-K filed by Bristol-Myers Squibb Company

      11-K - BRISTOL MYERS SQUIBB CO (0000014272) (Filer)

      6/6/25 2:24:02 PM ET
      $BMY
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BMY
    $FB
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • September 26, 2024 - FDA Approves Drug with New Mechanism of Action for Treatment of Schizophrenia

      For Immediate Release: September 26, 2024 Today, the U.S. Food and Drug Administration approved Cobenfy (xanomeline and trospium chloride) capsules for oral use for the treatment of schizophrenia in adults. It is the first antipsychotic drug approved to treat schizophrenia that targets cholinergic receptors as opposed to dopamine receptors, which has long been the standard of care.   “Schizophrenia is a leading

      9/26/24 6:42:20 PM ET
      $BMY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • June 14, 2024 - FDA Roundup: June 14, 2024

      For Immediate Release: June 14, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, the FDA issued a proposed exemption for certain cottage cheese products from the requirements of the Food Traceability Rule. The proposal would exempt Grade “A” cottage cheese that appears on the Interstate Milk Shippers List from the requirements of the r

      6/14/24 3:54:45 PM ET
      $MMSI
      $BMY
      Medical/Dental Instruments
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • March 8, 2024 - FDA Roundup: March 8, 2024

      For Immediate Release: March 08, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, the FDA announced proposed new regulations to provide animal drug sponsors with predictable requirements for the labeling of prescription and over-the-counter new animal drugs, as well as new animal drugs for use in animal feeds. The proposed content and

      3/8/24 3:26:46 PM ET
      $BMY
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BMY
    $FB
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 3 filed by new insider Shibutani Hiroshi Chris

      3 - BRISTOL MYERS SQUIBB CO (0000014272) (Issuer)

      6/16/25 6:47:45 PM ET
      $BMY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Executive Officer Boerner Christopher S. gifted 62,719 shares and received a gift of 62,719 shares, closing all direct ownership in the company (SEC Form 4)

      4 - BRISTOL MYERS SQUIBB CO (0000014272) (Issuer)

      6/16/25 6:43:52 PM ET
      $BMY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • EVP, Corporate Affairs Short Bartie Wendy converted options into 8,040 shares and covered exercise/tax liability with 3,334 shares (SEC Form 4)

      4 - BRISTOL MYERS SQUIBB CO (0000014272) (Issuer)

      6/4/25 5:37:59 PM ET
      $BMY
      Biotechnology: Pharmaceutical Preparations
      Health Care